Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of vYF Vaccine vs YF-VAX in Adults
NCT04942210Phase 2Active, not recruiting
- Sponsor
- Sanofi
- Start
- Jul 2021
- Primary completion
- Jun 2022
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of SP0218 in yellow fever (2 arms), sponsored by Sanofi. Primary endpoint: Percentage of Participants Who Achieved Seroconversion at 28 days. Started Jul 2021; status: active, not recruiting.
02
Drugs
SP0218
03
Conditions
yellow fever
Beyond the preview
Go deeper on NCT04942210.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04942210.